However, in pancreatic adenocarcinoma, although MSLN is commonly expressed, it does not correlate with cancer aggressiveness, indicating that MSLN’s expression and its impact on prognosis vary by cancer type [18]. The gene discussed is MSLN; the disease is pancreatic adenocarcinoma.